Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SNDX 6352

Drug Profile

SNDX 6352

Alternative Names: Anti-CSF-1R monoclonal antibody - Syndax Pharmaceuticals; SNDX-6352; UCB 6352

Latest Information Update: 15 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Developer Syndax Pharmaceuticals; UCB
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graft-versus-host disease
  • Phase I Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 10 Jan 2020 Phase-II clinical trials in Graft-versus-host disease (Treatment-experienced) in USA (IV)
  • 28 Dec 2019 No recent reports of development identified for phase-I development in Cancer(In volunteers) in USA (IV, Infusion)
  • 11 Dec 2019 Preliminary efficacy and adverse events data from a phase I trial graft-versus-host-disease released by Syndax Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top